

# Rodrigo Alonso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6280740/publications.pdf>

Version: 2024-02-01

32  
papers

2,242  
citations

304743

22  
h-index

395702

33  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1898  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	1.7	316
2	Lipoprotein(a) Levels in Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1982-1989.	2.8	283
3	Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 135, 2133-2144.	1.6	270
4	Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1278-1285.	2.8	221
5	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	163
6	Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2004-2010.	2.4	130
7	Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). <i>Lipids in Health and Disease</i> , 2011, 10, 94.	3.0	121
8	Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1029-1039.	2.8	99
9	Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. <i>Atherosclerosis</i> , 2017, 262, 8-13.	0.8	60
10	Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 948-957.	1.5	50
11	Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. <i>Clinical Biochemistry</i> , 2009, 42, 899-903.	1.9	48
12	Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. <i>Journal of Clinical Lipidology</i> , 2016, 10, 953-961.	1.5	44
13	The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2414-2424.	5.3	44
14	Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. <i>Journal of Clinical Lipidology</i> , 2015, 9, 607-617.	1.5	40
15	<p></p>Lomitapide: a review of its clinical use, efficacy, and tolerability</p>. <i>Core Evidence</i> , 2019, Volume 14, 19-30.	4.7	39
16	Liquid Biopsy of Extracellular Microvesicles Maps Coronary Calcification and Atherosclerotic Plaque in Asymptomatic Patients With Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 945-955.	2.4	39
17	Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2021, 42, 2201-2211.	2.2	33
18	Familial Hypercholesterolaemia Diagnosis and Management. <i>European Cardiology Review</i> , 2018, 13, 14.	2.2	32

#	ARTICLE	IF	CITATIONS
19	Detección de la hipercolesterolemia familiar: un modelo de medicina preventiva. Revista Espanola De Cardiologia, 2014, 67, 685-688.	1.2	29
20	Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. Journal of Clinical Lipidology, 2019, 13, 989-996.	1.5	29
21	Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. Journal of Clinical Lipidology, 2017, 11, 160-166.	1.5	23
22	Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?. Current Opinion in Lipidology, 2018, 29, 445-452.	2.7	22
23	Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study. Atherosclerosis, 2021, 317, 52-58.	0.8	16
24	Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2508-2515.	2.4	15
25	Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. Journal of Clinical Lipidology, 2021, 15, 584-592.	1.5	13
26	A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort. European Journal of Preventive Cardiology, 2022, 29, 795-801.	1.8	12
27	Dyslipidemia and aortic valve disease. Current Opinion in Lipidology, 2021, Publish Ahead of Print, 349-354.	2.7	11
28	Plasma PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISA. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1044-1045, 24-29.	2.3	10
29	Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?. Current Atherosclerosis Reports, 2022, 24, 427-434.	4.8	9
30	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 286, 40-45.	0.8	7
31	Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B. Medicina Clínica (English Edition), 2015, 145, 229-230.	0.2	3
32	Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 828-834.	0.6	3